All News


All series


All All News

How I learned I was "no evidence of active disease," was reminded of an important appointment and the other benefits that the OpenNotes movement wants to make available to all patients

The Food and Drug Administration (FDA) approved the immunotherapy combination of Yervoy (ipilimumab) plus Opdivo (nivolumab) to treat patients with intermediate- or poor-risk advanced renal cell carcinoma in the frontline setting.

Too often, the news, internet and social media focus on the sad stories. As survivors, it is up to us to focus on those stories that are positive and how survivors living their lives. I call it the living stories.

Patients with cancer are often asked when they’ll be done with chemotherapy or treatment. Those of us with blood cancers and bone marrow type of cancers such as aplastic anemia, myelodysplastic syndrome, lymphoma and leukemia, along with a host of other cancers sadly have to say, “never.”